Print Page Print Page  |  RSS Feeds RSS Feeds  |  E-mail Alerts E-mail Alerts  |  IR Contacts IR Contacts  |  Financial Tear Sheet Financial Tear Sheet

Roger G. Stoll, PH.D.
Chairman
Biography PhotoRoger G. Stoll, PH.D.
Chairman


Roger G. Stoll, PH.D. was appointed as a director in December 2008. From 2002 to 2008, he served as Chairman, Chief Executive Officer and President of Cortex Pharmaceuticals, Inc. (CORX:OTCBB), in August 2008 he was appointed Executive Chairman of the Board. He retired from Cortex Pharmaceuticals in August, 2012. From 2001 to 2002, he was a consultant to several east coast venture capital firms and startup ventures. From 1998 to 2001, he was Executive Vice President of Fresenius Medical... 
Simon Pedder, Ph.D.
Director
Simon Pedder, Ph.D.
Director


Simon Pedder, Ph.D. Dr. Pedder joined the Delcath Board of Directors in November 2017. Dr. Pedder is a scientist and pharmaceutical executive with a 30-year career in drug development. He currently serves as Chief Business and Strategy Officer at Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. During his long career in drug development, Dr. Pedder has held several leadership positions... 
William D. Rueckert
Director
William D. Rueckert
Director


Mr. Rueckert joined the Board of Directors in December 2014. Mr. Rueckert has served on many public and private corporate boards in both the life science and banking industries. He is currently President of Oyster Management Group, LLC, an investment partnership specializing in community banking. From 2007 until 2012 he served on the board of Novogen Ltd. (ASX, NASDAQ) a biotechnology company based in Sydney, Australia. He acted as Chairman from 2010 until 2012, and as acting CEO led the res... 

Jennifer Simpson, PhD., M.S.N., C.R.N.P.
Director
Biography PhotoJennifer Simpson, PhD., M.S.N., C.R.N.P.
Director


Jennifer Simpson joined Delcath as Executive Vice President, Global Marketing in March of 2012, was appointed Executive Vice President, Global Head of Business Operations in April 2013, and appointed Interim Co-President and Co-Chief Executive Officer in September 2013. In her current position Dr. Simpson has responsibility for global sales, marketing, regulatory affairs, quality assurance, clinical development and medical affairs activities. Prior to joining Delcath Dr. Simpson served as the Vi... 
Dr. Marco Taglietti
Director
Dr. Marco Taglietti
Director


Dr. Taglietti joined the Board of Directors in December 2014. Dr. Taglietti serves on the Board of Directors of NASDAQ-listed SCYNEXIS, Inc., a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives; and NephroGenex, Inc., a pharmaceutical company focused on the development of therapeutics to treat kidney disease. Prior to its recent acquisition, Dr. Taglietti served as Executive Vice President, Research and Development, and Chief Medica...